SunTrust Robinson Humphrey analyst Edward Nash downgraded Adverum Biotechnologies (NASDAQ: ADVM) from Buy to Hold with a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change Downgrades

Adverum Biotechnologies (ADVM) PT Lowered to $4.50 at Chardan Capital MarketsNovember 2, 2018 9:05 AM Raymond James Downgrades Adverum Biotechnologies (ADVM) to Market PerformNovember 2, 2018 5:10 AM Adverum Biotechnologies (ADVM) PT Lowered to $8 at Piper JaffrayNovember 2, 2018 3:04 AM After-Hours Movers 11/01: (PACB) (PETX) (ANET) Higher; (PBYI) (OLED) (AAPL) Lower (more...)November 1, 2018 6:16 PM Adverum Biotechnologies (ADVM) to discontinue development of ADVM-043November 1, 2018 5:23 PM Adverum Biotechnologies Provides Program UpdatesNovember 1, 2018 4:15 PM